Ozempic, Fatty Liver, and the MASH Trial Data

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide side effects and safety hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

A Number That Changed the Conversation

When Rachel, a 47-year-old project manager in Charlotte, got her labs back last September, the ALT reading stopped her cold: 68 U/L, flagged in red, nearly double the upper limit. Her primary care doctor mentioned "fatty liver" and told her to lose weight. Standard advice, the kind that sounds simple and isn't. Seven months into compounded semaglutide therapy, her ALT was 31. She'd lost 38 pounds. "I didn't even know my liver was the thing to watch," she told her prescriber at a follow-up. "I thought this was just about the scale."

Rachel's experience tracks with something increasingly visible in the clinical literature: semaglutide doesn't just affect body weight. It appears to affect the liver in ways that matter, particularly for the roughly 30 percent of American adults living with some degree of non-alcoholic fatty liver disease. This article is the trial-data view of ozempic fatty liver, written for patients who want the same information their clinician trained on, not a marketing gloss.

This guide sits inside the broader Compounded Semaglutide Side Effects and Safety cluster, which is part of the compounded semaglutide pillar guide.

A note on the preparation itself: compounded semaglutide is prepared by a licensed compounding pharmacy under a clinician prescription. It uses the same active ingredient as Wegovy and Ozempic. It is not FDA-approved. The clinical evidence base for the molecule comes from trials of the branded products. The compounded preparation has not been independently tested in randomized trials at the same scale.

The Safety Dataset, Briefly

The published trial record for semaglutide is, by obesity medicine standards, genuinely extensive. Across STEP-1, STEP-3, STEP-4, SUSTAIN-6, LEADER, and SELECT, gastrointestinal events were the most common adverse effects. Serious adverse events were uncommon. Pancreatitis was reported in a small number of patients, and the rate did not differ significantly between active and placebo arms in SELECT or LEADER, though any individual case obviously warrants attention.

The Wegovy and Ozempic labels include a boxed warning regarding thyroid C-cell tumors based on rodent data. Human evidence for that risk has not materialized at population scale in the large outcome trials. Most prescribers screen for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 before writing a prescription.

What the First Eight Weeks Actually Feel Like

The early weeks of therapy are where patients and their GI tracts negotiate terms. Nausea, decreased appetite, mild bloating, constipation, intermittent reflux. Roughly 20 percent of patients in STEP-1 reported nausea at some point during the trial; severe nausea was considerably less common. The pattern is almost always dose-related: it appears at or shortly after a dose increase and fades within one to two weeks.

Fatigue is trickier to attribute. It can reflect the medication, or it can simply reflect the fact that someone eating 1,400 calories instead of 2,200 feels tired. (That's a food problem, not a drug problem.) Patients with persistent fatigue benefit from a check of basic labs, hydration status, and protein intake before anyone adjusts the medication.

Here's the thing about side effect intensity: it does not predict results. Trial data from both STEP-1 and STEP-3 show that patients with mild GI tolerability and patients with pronounced symptoms both achieved meaningful weight loss. Suffering more does not mean working harder.

The Liver Story, and Why It Matters

This is where the ozempic fatty liver conversation gets genuinely interesting.

The relationship between semaglutide and liver outcomes has been studied through trials in patients with metabolic-associated steatohepatitis (MASH, previously called NASH). Published programs evaluating semaglutide in this population have reported improvements in liver fat content and in biomarker measures of liver inflammation. Whether this leads to a labeled liver-specific indication is its own regulatory question, one that moves at its own glacial pace.

Think of the liver like a sponge that's been soaking in grease for years. Weight loss wrings some of that grease out. But semaglutide may be doing more than just facilitating weight loss; some data suggest direct metabolic effects on hepatic fat processing, independent of the scale number. The clinical conversation about this is still evolving, and "evolving" here is honest, not hedging.

For patients with elevated liver enzymes or a known diagnosis of fatty liver disease, starting semaglutide therapy includes a discussion of potential liver-related benefits alongside the standard risk-benefit calculus. Active liver disease (particularly cirrhosis or severe hepatic impairment) warrants specific clinical evaluation before initiating GLP-1 therapy. Baseline liver enzymes are commonly checked before starting and during ongoing care.

When to Pick Up the Phone

Most patients set their threshold for calling the prescriber too high. Lower it. Vomiting for more than one day, severe upper abdominal pain (especially radiating to the back), signs of dehydration, jaundice, persistent severe headache, or vision changes are reasons to call promptly.

Most GI side effects don't rise to that threshold and can be managed with a dose hold or symptomatic care. But the cost of calling unnecessarily is zero. The cost of waiting too long on something like pancreatitis is not.

The Boring Truth About Tolerability

The four most reliable interventions for GI tolerability are almost disappointingly simple:

Small, slow meals
Lower-fat content during the first two weeks after any dose change
Adequate hydration (more than most people think)
Avoiding very rich or fried foods around dose escalation

Anti-nausea medication is appropriate for some patients and is a routine tool in the prescriber's kit. There's no award for white-knuckling through preventable nausea.

Four Misconceptions That Keep Circulating

"Compounded is basically the same as FDA-approved." It is not. The active ingredient is the same molecule, yes. But compounding pharmacies operate under a different regulatory framework, with different oversight. Compounded preparations are not FDA-approved. That distinction matters, and pretending it doesn't helps no one.

"If I'm not nauseous, it's not working." See above. No reliable evidence supports this. It's a folk belief that persists because it feels intuitive, which is exactly the kind of belief that trial data exist to correct.

"The medication does the entire job." STEP-3, which paired semaglutide with a structured lifestyle intervention, produced greater mean weight loss than STEP-1, which used medication alone. Lifestyle is additive. It is not optional for durable outcomes.

"If I stop, I'll just go back to where I started." Partly true, which is important to understand. STEP-4 documented partial regain over the 48 weeks after switching from active drug to placebo at week 20. The chronic biology of weight regulation reasserts itself without pharmacologic support, the same way blood pressure drifts back up when you stop the antihypertensive. This isn't a failure of willpower. It's physiology.

What Actually Predicts Good Outcomes

The clinician relationship matters more than the brand name on the vial. A program that supports honest clinical conversation, responds to side effects with appropriate adjustments, and provides clear follow-up between refills produces better outcomes than one with slick marketing and weak clinical infrastructure. That's an opinion, but it's one backed by watching this space closely for years.

Individual response varies. The trial means describe averages, not individuals. And lifestyle context matters more on therapy than it does at higher baseline intake, because every calorie consumed carries more nutritional weight when total intake is reduced. A patient eating 1,400 calories of processed food and a patient eating 1,400 calories of balanced protein, fiber, and fat are on very different trajectories, even at the same dose.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide Side Effects and Safety cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Are the side effects of compounded semaglutide different from Wegovy or Ozempic?

The active ingredient is the same molecule. The side effect profile reported in compounded semaglutide programs mirrors what was reported in SUSTAIN, STEP-1, and STEP-3 for the branded products. Compounded preparations are not FDA-approved and have not been independently studied in the same way.

When should a side effect trigger a call to the prescriber?

Severe abdominal pain, persistent vomiting, signs of dehydration, jaundice, or vision changes are reasons to contact the prescribing clinician promptly. Most GI side effects are dose-related and improve with adjustment.

Do side effects predict effectiveness?

No. There is no reliable evidence that nausea or other GI side effects predict greater weight loss. Trial data show meaningful weight loss in patients with minimal side effects as well as those with more pronounced symptoms.

Can semaglutide help with fatty liver disease?

Published trials in patients with MASH have reported improvements in liver fat content and biomarkers of liver inflammation. Whether this translates to a formal liver-specific indication is still a regulatory question. Patients with existing fatty liver disease should discuss the potential benefits and risks with their prescriber.

Should I get liver labs before starting semaglutide?

Baseline liver enzymes are commonly checked before initiating therapy and during ongoing care, depending on clinical profile. This is standard practice, not a red flag.

Is fatty liver a contraindication to starting semaglutide?

Fatty liver alone is generally not a contraindication. Active liver disease, particularly cirrhosis or severe hepatic impairment, warrants specific clinical evaluation before starting GLP-1 therapy.

How long does it take to see liver enzyme improvement?

This varies by individual. Some patients see normalization within a few months of therapy; others take longer. The trajectory typically tracks with weight loss but may also reflect direct metabolic effects of the medication.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.